NCT03334084View on ClinicalTrials.gov

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Bioavailability Study
Interventions
DRUG

ARGX-113

intravenous or subcutaneous administration

Trial Locations (1)

Unknown

QPS Netherlands B.V., Groningen

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY